SynthesisAnnals of the rheumatic diseases2014
Greater body mass independently predicts less radiographic progression on X-ray and MRI over 1-2 years.
Synthesis in Annals of the rheumatic diseases, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 48 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
48 citing papers in PubMed, 3 syntheses or guidelines pooled it, 99 citations in OpenAlex.
- When does obesity exert its effect in conferring risk of developing RA: a large study in cohorts of symptomatic persons at risk.RMD open · 2024Pooled it
- A systematic review of the association of obesity with the outcomes of inflammatory rheumatic diseases.Singapore medical journal · 2019Pooled it
- The effects of weight loss approaches on bone mineral density in adults: a systematic review and meta-analysis of randomized controlled trials.Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA · 2016Pooled it
- Obesity is a risk factor for poor response to treatment in early rheumatoid arthritis: a NORD-STAR study.RMD open · 2024Trial
- Trial
- Predictors of disease activity and structural progression after treatment with adalimumab plus methotrexate or continued methotrexate monotherapy in patients with early rheumatoid arthritis and suboptimal response to methotrexate.Annals of the rheumatic diseases · 2018Trial
- Body mass index and clinical response to intravenous or subcutaneous abatacept in patients with rheumatoid arthritis.Clinical rheumatology · 2017Trial
- Validity of early MRI structural damage end points and potential impact on clinical trial design in rheumatoid arthritis.Annals of the rheumatic diseases · 2016Trial
- Association of Demographic, Clinical, and Environmental Factors With Disease Severity in Adult Myasthenia Gravis: A Multicenter Cross-Sectional Study.CNS neuroscience & therapeutics · 2026Article
- Bone metabolism and inflammation drive structural damage in rheumatoid arthritis: clustering and multivariable analysis.Therapeutic advances in musculoskeletal disease · 2026Article
- Observational
- Metabolic Syndrome, Adipokines, and Response to Advanced Therapies in Rheumatoid Arthritis.Arthritis & rheumatology (Hoboken, N.J.) · 2025Article
- Improving our understanding of the paradoxical protective effect of obesity on radiographic damage: a large magnetic resonance imaging-study in early arthritis.Rheumatology (Oxford, England) · 2024Article
- Lower body mass and lower adiposity are associated with differential responses to two treatment strategies for rheumatoid arthritis.Annals of the rheumatic diseases · 2024Article
- Joint-level responses to tofacitinib and methotrexate: a post hoc analysis of data from ORAL Start.Arthritis research & therapy · 2023Article
- Adipocytokines and achievement of low disease activity in rheumatoid arthritis.Seminars in arthritis and rheumatism · 2022Article
- Obesity and the Risk of Incident Chronic Opioid Use in Rheumatoid Arthritis.Arthritis care & research · 2021Article
- The Assessment of Muscle Mass and Function in Patients with Long-Standing Rheumatoid Arthritis.Journal of clinical medicine · 2021Article
- Evaluation of the impact of age and adiposity on a multi-biomarker disease activity score before and after adjustment.Clinical rheumatology · 2021Article
- Bone Loss and Radiographic Damage Profile in Rheumatoid Arthritis Moroccan Patients.Journal of bone metabolism · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 6 institutions in 3 countries.
Funding
Abstract
introductionGreater body mass index (BMI) has been associated with less radiographic progression in rheumatoid arthritis (RA). We evaluated the association between BMI and joint damage progression as measured by X-ray and MRI.
methods1068 subjects with RA from two clinical trials of golimumab (GO-BEFORE and GO-FORWARD) had radiographs performed at weeks 0, 52 and 104 and evaluated using the van der Heijde-Sharp (vdHS) scoring system. Contrast-enhanced MRIs of the dominant wrist and hand were obtained at weeks 0, 12, 24, 52 and 104. Multivariable logistic regression evaluated the risk of radiographic progression for each BMI category (<25, 25-30, >30 kg/m(2)). Within GO-BEFORE, piecewise, robust generalised estimating equations marginal models assessed the probability of MRI erosion progression for each BMI category. Multivariable linear regression models assessed baseline associations between BMI and bone oedema (a precursor of bone erosion).
resultsHigher BMI category was associated with a lower probability of progression in vdHS score at weeks 52 and 104 independent of potential confounders. Higher BMI was also independently associated with a lower probability of progression in MRI erosion score over 2 years. Subjects with greater BMI demonstrated less bone oedema independent of differences in other disease severity measures, including MRI synovitis in the same joints.
conclusionsGreater BMI is associated with a lower risk of progression on X-ray and MRI over 2 years. Subjects with greater BMI also demonstrate less bone oedema at baseline. Greater BMI may indicate a less aggressive RA phenotype and aid in risk stratification.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.